Search This Blog

Wednesday, November 4, 2026

Viridian beats, $955M cash plus sales fund plans to profitability

 

Viridian Therapeutics Inc reports fiscal Q3 2026 results with revenue $25.8M (-64% YoY), beats revenue estimates

  • Q3 2026 included $24.7M in first-quarter Lumvoa net product revenue
  • Company says $955M cash plus sales fund plans to profitability
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)